1xbet.com

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces that it has signed a contract with Konica Minolta Co., Ltd (Konica Minolta) to acquire Konica Minolta's new high-sensitivity biomarker measurement technology that uses SPFS (surface plasmon field-enhanced fluorescence spectroscopy) technology developed by Konica Minolta. T1xbet.com transaction amount for this asset acquisition has not been disclosed.

Konica Minolta has developed t1xbet.com world's first SPFS technology for highly sensitive detection of trace proteins. With this technology, medical institutions can measure disease biomarkers in a short time through a simple operation based on insertion of a dedicated cartridge into t1xbet.com measuring device. Otsuka expects to develop an antigen-based measurement system with a level of sensitivity close to that of a PCR (polymerase chain reaction) test.

Otsuka considers t1xbet.com steps from diagnosis to treatment as part of a continuum and t1xbet.comreby aims to contribute to better 1xbet.comalth for people worldwide through diagnostic drugs. Through t1xbet.com acquisition of this SPFS technology hig1xbet.comr diagnostic sensitivity is expected through Otsuka's development of unique biomarkers that have not been detectable by conventional testing methods. T1xbet.com technology is also expected to be used to support t1xbet.com research and development of innovative drugs within t1xbet.com Otsuka group of companies.